Georgia Bio
Georgia Bio is dedicated to advancing the life sciences industry in Georgia through advocacy, education, and industry initiatives. It promotes policy development, community programs, and industry collaborations to foster innovation and growth in the bioscience sector. The organization also actively advocates for policies that lower healthcare costs, support innovation, and enhance industry growth, including efforts related to drug pricing transparency and access to breakthrough technologies. It hosts industry events, career fairs, and provides resources for funding and collaboration to support the growth of the biotech and health sectors in Georgia.
Industries
Nr. of Employees
small (1-50)
Georgia Bio
Services
Legislative monitoring, policy development, committee engagement and advocacy on state and federal issues that affect life‑sciences stakeholders; includes coordination with national trade groups and federal advocacy activities.
Programs for K–12 teachers and students, an equipment depot for classrooms, career hub resources, career fair aggregation, and professional development to build life‑sciences talent pipelines.
Mentorship, incubator referrals, access‑to‑capital resources, structured program cohorts and investor/mentor matchmaking for early‑stage life‑sciences companies.
Scanning of federal and other non‑dilutive funding sources, distribution of monthly funding reports, monthly webinars on opportunities and strategy, and forums connecting companies with investors and funding resources.
Planning and hosting of annual summits, conferences, poster sessions, company showcases and topical forums to convene stakeholders and present scientific work.
Negotiated discounts and curated purchasing agreements on products and services relevant to life‑sciences operations delivered as a member benefit program.
Legislative monitoring, policy development, committee engagement and advocacy on state and federal issues that affect life‑sciences stakeholders; includes coordination with national trade groups and federal advocacy activities.
Programs for K–12 teachers and students, an equipment depot for classrooms, career hub resources, career fair aggregation, and professional development to build life‑sciences talent pipelines.
Mentorship, incubator referrals, access‑to‑capital resources, structured program cohorts and investor/mentor matchmaking for early‑stage life‑sciences companies.
Scanning of federal and other non‑dilutive funding sources, distribution of monthly funding reports, monthly webinars on opportunities and strategy, and forums connecting companies with investors and funding resources.
Planning and hosting of annual summits, conferences, poster sessions, company showcases and topical forums to convene stakeholders and present scientific work.
Negotiated discounts and curated purchasing agreements on products and services relevant to life‑sciences operations delivered as a member benefit program.
Expertise Areas
- State and federal life‑sciences policy advocacy and legislative monitoring
- Medtech regulatory strategy and quality management aligned with ISO 13485 principles
- Clinical trial patient engagement and rare disease advocacy
- Workforce development and STEM education program delivery
Key Technologies
- ISO 13485-aligned quality management systems
- Good Laboratory Practice (GLP) preclinical testing
- AI and machine learning for healthcare and medical imaging
- Predictive analytics and data‑driven health analytics
News & Updates
Annual summit bringing together innovators, investors, policymakers, and ecosystem leaders to shape the future of health innovation in Georgia.
Scheduled for August 26-27, 2025, at the Sandy Springs Performing Arts Center, focusing on health innovation and policy.
Discussion on recent federal policy shifts impacting the biotech industry and Georgia's role in advocacy.
Analysis of current challenges and opportunities for early-stage biotech companies in the U.S.
Updated state fact sheets on the 340B drug pricing program in Georgia.
Acadia acquired Levo Therapeutics and plans to initiate a Phase 3 study for ACP-101, a treatment for hyperphagia in Prader-Willi syndrome.
Annual summit bringing together innovators, investors, policymakers, and ecosystem leaders to shape the future of health innovation in Georgia.
Scheduled for August 26-27, 2025, at the Sandy Springs Performing Arts Center, focusing on health innovation and policy.
Discussion on recent federal policy shifts impacting the biotech industry and Georgia's role in advocacy.
Analysis of current challenges and opportunities for early-stage biotech companies in the U.S.
Updated state fact sheets on the 340B drug pricing program in Georgia.
Acadia acquired Levo Therapeutics and plans to initiate a Phase 3 study for ACP-101, a treatment for hyperphagia in Prader-Willi syndrome.